DDInter1867 DDInter1934
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456]
Triflupromazine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Trifluoperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Triflupromazine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Trifluoperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vilanterol
Triflupromazine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vilanterol
Triflupromazine {u} (Compound) resembles {v} (Compound) Alimemazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Triflupromazine {u} (Compound) resembles {v} (Compound) Perphenazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Insulin degludec {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Triflupromazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Pipotiazine {u} (Compound) resembles {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Desipramine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Triflupromazine {u} (Compound) resembles {v} (Compound) Perphenazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Empagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Triflupromazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Triflupromazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Triflupromazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Triflupromazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Triflupromazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Triflupromazine (Compound) resembles Pipotiazine (Compound) and Pipotiazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Triflupromazine (Compound) resembles Desipramine (Compound) and Desipramine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Triflupromazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol